Strasbourg, France, April 1, 2025 – Novalix is pleased to announce the appointment of Felix von Haniel as Senior Vice-President of Business Development and Marketing and will be focusing on the UK and US—two key markets driving the firm’s growth strategy.
With 25 years of international experience in business development and strategy, Felix von Haniel has held senior roles at innovative biotech and CRO companies, including Evotec, Cyprotex, and Ncardia. A molecular biologist by training and an MBA graduate from Cambridge University, he seamlessly connects science and business to accelerate company growth.
Throughout his career, Felix has built and led global BD teams, driven multi-million euro revenue expansions, and shaped impactful marketing and commercial strategies. Beyond his corporate roles, he is an active investor in biotech ventures, with a track record of successful exits and a strong commitment to advancing scientific innovation.
“Joining Novalix means stepping into a role where science meets strategy at full speed. With ambitious goals and a sharp focus on the UK and US, there’s real momentum here—and I’m looking forward to turning that into impact.”
Felix von Haniel’s expertise and strategic vision will be instrumental in strengthening Novalix’s presence in the UK and US markets.
We are excited to welcome him to the team!